Synthesis and Biological Evaluation of a New Class of Geldanamycin Derivatives as Potent Inhibitors of Hsp90
Citations Over TimeTop 11% of 2004 papers
Abstract
The heat shock protein Hsp90 has increasingly become an important therapeutic target especially for treatment of cancers. Inhibition of the ATPase activity of Hsp90 by natural products (e.g., 17-allylaminogeldanamycin or radicicol) leads to the ubiquitination of oncogenic client proteins such as Her-2, Raf-1, and p-Akt followed by their proteasomal degradation. Hsp90 inhibitors simultaneously target multiple oncogenic proteins and provide an advantage for cancer therapy due to the potential for increased efficacy and overcoming drug resistance. In an effort to convert geldanamycin into a druglike compound with better pharmacokinetic properties and efficacy in human tumor xenograft models, geldanamycin was derivatized on the 17-position to prepare new analogues such as 17-geldanamycin amides, carbamates, and ureas and 17-arylgeldanamycins. All the compounds were first evaluated ex vivo using a cell-based Her-2 degradation assay and in vitro using biochemical assays that measure recombinant Hsp90 (rHsp90) competitive binding and changes in rHsp90 conformation. In addition, we confirmed the selectivity of geldanamycin analogues for Hsp90 derived from tumor cells using a novel cell lysate binding assay.
Related Papers
- → Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs(2002)236 cited
- → Heat Shock Proteins: A Potential Anticancer Target(2011)34 cited
- → Development of VER-50589 analogs as novel Hsp90 inhibitors(2023)1 cited
- → Stable disease for four years in metastatic malignant melanoma treated with the heat shock protein inhibitor 17-AAG(2006)
- → 81 Potential clinical application of a novel Heat Shock Protein 90 inhibitor CH5164840: preclinical efficacy in mono therapy and combination therapy(2010)